Proton beam therapy and localised prostate cancer: Current status and controversies

British Journal of Cancer

Volumn 108, Issue 6, 2013, Pages 1225-1230

  Efstathiou, J A ^a   Gray, P J ^a   Zietman, A L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

HEALTH CARE COSTS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTON THERAPY;

EID: 84876418920     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.100     Document Type: Review

References (49)

1. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P, Pinzi V, Arcangeli G (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84: 1172-1178.
2. Athar BS, Bednarz B, Seco J, Hancox C, Paganetti H (2010) Comparison of out-of-field photon doses in 6MV IMRT and neutron doses in proton therapy for adult and pediatric patients. Phys Med Biol 55: 2879-2891.
3. Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, Armstrong K (2011) Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 81: e325-e334.
4. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R (2011) Phase I doseescalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J Clin Oncol 29: 2020-2026.
5. Brenner DJ, Elliston CD, Hall EJ, Paganetti H (2009) Reduction of the secondary neutron dose in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator. Phys Med Biol 54: 6065-6078.
6. Brenner DJ, Hall EJ (2008) Secondary neutrons in clinical proton radiotherapy: a charged issue. Radiother Oncol 86: 165-170.
7. Carabe-Fernandez A, Paganetti H (2011) Clinical consequences of relative biological effectiveness (RBE) variations in proton radiotherapy of the prostate, brain, and liver. Int J Radiat Oncol Biol Phys 81: S725-S726.
8. Childs SK, Kozak KR, Friedmann AM, Yeap BY, Adams J, MacDonald SM, Liebsch NJ, Tarbell NJ, Yock TI (2012) Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 82: 635-642.
9. Chung CS, Keating N, Yock TI, Tarbell NJ (2008) Comparative analysis of secondary malignancy risk in patients treated with proton therapy versus conventional photon therapy. Int J Radiat Oncol Biol Phys 72: S8.
10. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ (2011) Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys 81: 1005-1009.
11. Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, Shipley WU (2012) Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys 82: e25-e31.
12. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13: 43-54.
13. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353: 267-272.
14. Emanuel EJ, Pearson SD (2012) Is costs more, but is it worth more? The New York Times, 2 January 2012.
15. Fontenot JD, Lee AK, Newhauser WD (2009) Risk of secondary malignant neoplasms from proton therapy and intensity-modulated X-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 74: 616-622.
16. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P (2002) Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167: 123-126.
17. Goitein M (2008) Magical protons? Int J Radiat Oncol Biol Phys 70: 654-656.
18. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA (2013) Patient-reported outcomes following 3-dimensional conformal, intensity-modulated or proton beam radiotherapy for localized prostate cancer. Cancer; e-pub ahead of print 22 February 2013; doi:10.1002/cncr.27956.
19. Hellman S, Hellman DS (1991) Of mice but not men. Problems of the randomized clinical trial. N Engl J Med 324: 1585-1589.
20. Jarosek S, Elliott S, Virnig BA (2011) Proton beam radiotherapy in the U.S. Medicare population: growth in use between 2006 and 2009: Data Points # 10. 2012 May 7. In: Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Available from: http://www.ncbi.nlm.nih.gov/books/NBK97147/.
21. Johnson CY (2012) Proton beams vs. radiation. The Boston Globe, 14 May 2012.
22. Kim S, Shen S, Moore DF, Shih W, Lin Y, Li H, Dolan M, Shao YH, Lu-Yao GL (2011) Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 60: 908-916.
23. Konski A, Speier W, Hanlon A, Beck JR, Pollack A (2007) Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 25: 3603-3608.
24. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68: 1424-1430.
25. MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, Bortfeld T, Tarbell NJ, Yock T (2008) Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71: 979-986.
26. Mendenhall NP, Li Z, Hoppe BS, Marcus Jr. RB, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Costa J, Henderson R (2012) Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 82: 213-221.
27. Michalski JM, Yan Y, Watkins-Bruner D, Walter B, Winter K, Galvin JM, Bahary J, Morton GC, Parliament MB, Sandler H (2011) Preliminary analysis of 3D-CRT vs. IMRT on the high dose arm of the rtog 0126 prostate cancer trial: toxicity report. Int J Radiat Oncol Biol Phys 81: S1-S2.
28. Miralbell R, Lomax A, Cella L, Schneider U (2002) Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54: 824-829.
29. Nihei K, Ogino T, Onozawa M, Murayama S, Fuji H, Murakami M, Hishikawa Y (2011) Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys 81: 390-396.
30. Ollendorf DA, Hayes J, McMahon P, Kuba M, Pearson SD (2009) Management Options for Low-Risk Prostate Cancer: A Report On Comparative Effectiveness And Value. Institute for Clinical and Economic Review: Boston, MA, USA.
31. Pollack A (2007) Cancer fight goes nuclear, with heavy price tag. The New York Times, 26 December 2007.
32. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostatecancer survivors. N Engl J Med 358: 1250-1261.
33. Shah A, Paly JJ, Efstathiou JA, Bekelman JE (2012a) Physician Evaluation of Internet Health Information on Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys; doi:pii: S0360-3016(12)03739-X. 10.1016/j.ijrobp.2012. 10.039.
34. Shah A, Efstathiou JA, Paly JJ, Halpern SD, Bruner DW, Christodouleas JP, Coen JJ, Deville Jr. C, Vapiwala N, Shipley WU, Zietman AL, Hahn SM, Bekelman JE (2012b) Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensitymodulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 83: e13-e19.
35. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC (2012) Intensitymodulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307: 1611-1620.
36. Shipley W, Verhey L, Munzenrider J, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, Heney NM, Goitein M (1995) Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 30: 3-12.
37. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL (2010) Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 303: 1046-1053.
38. Tang S, Both S, Bentefour H, Paly JJ, Tochner Z, Efstathiou J, Lu HM (2012) Improvement of prostate treatment by anterior proton fields. Int J Radiat Oncol Biol Phys 83: 408-418.
39. Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, Delaney TF, Shipley WU (2007) Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 69: 444-453.
40. Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu HM, Engelsman M, Merrick S, Cheng CW, Wong JR, Zietman AL (2011) Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 80: 928-937.
41. van Loon J, Grutters J, Macbeth F (2012) Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? Lancet Oncol 13: e169-e177.
42. Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie C, Lawlor P, Henderson R, Li Z, Lin L, Olivier K, Keole S (2008) Dosevolume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70: 744-751.
43. Wang Y, Efstathiou JA, Sharp GC, Lu HM, Ciernik IF, Trofimov AV (2011) Evaluation of the dosimetric impact of interfractional anatomical variations on prostate proton therapy using daily in-room CT images. Med Phys 38: 4623-4633.
44. Wilson RR (1946) Radiological use of fast protons. Radiology 47: 487-491.
45. Yoon M, Ahn SH, Kim J, Shin DH, Park SY, Lee SB, Shin KH, Cho KH (2010) Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 77: 1477-1485.
46. Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP (2013) Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 105: 25-32.
47. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876-881.
48. Zietman A, Tepper J, Goitein M (2010b) Technology evolution: is it survival of the fittest? J Clin Oncol 28: 4275-4279.
49. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ (2010a) A randomized trial comparing conventional dose conformal radiation therapy with high-dose in early stage adenocarcinoma of the prostate. Long-term results from Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09. J Clin Oncol 28: 1106-1111.